media release by Tania Ewing
Each year in Australia over 1000 people are
diagnosed with acute myeloid leukaemia (AML), an aggressive blood cancer. Less
than one third of AML patients survive 5 years beyond diagnosis. Researchers
from Monash University have discovered a key reason why this disease is so
difficult to treat and therefore cure.
The study, led by Associate Professor Ross Dickins from the Australian Centre for Blood Diseases, is published today(TBC) in the prestigious journal Cell Stem Cell. The paper identifies an
important new concept relevant to clinicians involved in the diagnosis and
treatment of AML patients.
AML is characterised by an overproduction of immature
white blood cells that fail to mature properly. These leukaemia cells crowd the
bone marrow, preventing it from making normal blood cells. In turn this causes
anaemia, infections, and if untreated, death. Acute myeloid leukemia (AML)
remains a significant health problem, with poor outcomes despite chemotherapy
and stem cell transplantation.

